by Barry101 | Jan 23, 2025 | Press Release
OCALA, Fla., Jan. 23, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the Efficacy and Safety of Ampligen in Patients With...
by Barry101 | Jan 22, 2025 | Press Release
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of Ampligen has been observed to stimulate strong innate immune response,...
by Barry101 | Jan 15, 2025 | Press Release
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces – Expected milestones over the course of the next 18 months...
by Barry101 | Dec 17, 2024 | Press Release
A Plan for Compliance has been UndertakenOCALA, Fla., Dec. 17, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (the...
by Barry101 | Dec 17, 2024 | Press Release
OCALA, Fla. – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elected three of the Company’s incumbent directors...
by Barry101 | Dec 16, 2024 | Press Release
Urges Shareholders to Ensure Their Voices Are Heard and to Protect Their Investment by Supporting Current Board Believes Incumbent Board is Best Positioned to Continue Overseeing the Clinical Development of Ampligen and Deliver Long-Term Value for All Shareholders...
